Britain and America have signed a significant commercial pact that will guarantee zero levies on UK pharmaceutical exports entering the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to boost funding on medicines through the NHS. This move ensures that duties on these crucial goods will remain at zero for a timeframe of 36 months.
This development is in response to earlier statements to significantly raise import taxes on patented pharmaceutical imports, with potential rates floated up to double the cost.
"This agreement with the UK strengthens the worldwide climate for new treatments and brings much-needed fairness to American-British pharmaceutical trade," a release noted.
Economic Importance
Medicines are one of the Britain's most significant goods shipped to the US, which is easily the largest buyer for major British pharmaceutical firms.
Trade data show that in the year leading up to last September, the UK sold drugs totaling £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that period.
"This agreement protects employment, boosts funding and paves the way for the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Detailed UK Commitments
The agreement includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be restricted at fifteen percent. In the past, refunds topped 20%.
Broader Context
The pact follows a ongoing row between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by assertions that American patients were charged a premium for the identical medicines than consumers in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while substantial funding commitments have been directed toward American operations.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a share of its total funding over the previous ten-year period.
